JP2020536518A5 - - Google Patents

Download PDF

Info

Publication number
JP2020536518A5
JP2020536518A5 JP2020517588A JP2020517588A JP2020536518A5 JP 2020536518 A5 JP2020536518 A5 JP 2020536518A5 JP 2020517588 A JP2020517588 A JP 2020517588A JP 2020517588 A JP2020517588 A JP 2020517588A JP 2020536518 A5 JP2020536518 A5 JP 2020536518A5
Authority
JP
Japan
Prior art keywords
seq
cancer
amino acid
fusion protein
acid residues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2020517588A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020536518A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/053197 external-priority patent/WO2019067770A1/en
Publication of JP2020536518A publication Critical patent/JP2020536518A/ja
Publication of JP2020536518A5 publication Critical patent/JP2020536518A5/ja
Priority to JP2023081001A priority Critical patent/JP7702445B2/ja
Withdrawn legal-status Critical Current

Links

JP2020517588A 2017-09-27 2018-09-27 免疫調節融合タンパク質 Withdrawn JP2020536518A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023081001A JP7702445B2 (ja) 2017-09-27 2023-05-16 免疫調節融合タンパク質

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762564145P 2017-09-27 2017-09-27
US62/564,145 2017-09-27
PCT/US2018/053197 WO2019067770A1 (en) 2017-09-27 2018-09-27 IMMUNOMODULATORY FUSION PROTEINS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023081001A Division JP7702445B2 (ja) 2017-09-27 2023-05-16 免疫調節融合タンパク質

Publications (2)

Publication Number Publication Date
JP2020536518A JP2020536518A (ja) 2020-12-17
JP2020536518A5 true JP2020536518A5 (cg-RX-API-DMAC7.html) 2021-10-21

Family

ID=65902489

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020517588A Withdrawn JP2020536518A (ja) 2017-09-27 2018-09-27 免疫調節融合タンパク質
JP2023081001A Active JP7702445B2 (ja) 2017-09-27 2023-05-16 免疫調節融合タンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023081001A Active JP7702445B2 (ja) 2017-09-27 2023-05-16 免疫調節融合タンパク質

Country Status (13)

Country Link
US (2) US11834492B2 (cg-RX-API-DMAC7.html)
EP (1) EP3688037A4 (cg-RX-API-DMAC7.html)
JP (2) JP2020536518A (cg-RX-API-DMAC7.html)
KR (1) KR102757384B1 (cg-RX-API-DMAC7.html)
CN (2) CN111511769B (cg-RX-API-DMAC7.html)
AU (2) AU2018338612A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020006115A2 (cg-RX-API-DMAC7.html)
CA (1) CA3077223A1 (cg-RX-API-DMAC7.html)
EA (1) EA202090838A1 (cg-RX-API-DMAC7.html)
IL (1) IL273626B2 (cg-RX-API-DMAC7.html)
MX (1) MX2020003672A (cg-RX-API-DMAC7.html)
SG (1) SG11202002826VA (cg-RX-API-DMAC7.html)
WO (1) WO2019067770A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10906957B2 (en) 2016-09-27 2021-02-02 Epicentrx, Inc. Immunomodulatory fusion proteins
US20230043257A1 (en) * 2020-01-21 2023-02-09 Jinyu Zhang Pharmaceutical composition and use thereof
EP4165086A4 (en) * 2020-09-16 2024-07-31 Suzhou Neologics Bioscience Co., Ltd. Pd-l1 antibodies, fusion proteins, and uses thereof
CN113480662B (zh) * 2021-06-29 2022-07-22 北京双因生物科技有限公司 包含cd40抗体和il-15的融合蛋白及其制备方法和用途
CN116143946B (zh) * 2022-01-05 2025-12-09 赛德特生物制药有限公司 一种用于免疫治疗的新型融合蛋白、基因、重组载体、宿主细胞及应用
CN122555725A (zh) * 2024-01-08 2026-08-11 上药生物治疗(香港)有限公司 膜表达il-10及其用途
WO2025221843A1 (en) * 2024-04-17 2025-10-23 Baylor College Of Medicine Methods and compositions for suppressing immune cell activation

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5525491A (en) 1991-02-27 1996-06-11 Creative Biomolecules, Inc. Serine-rich peptide linkers
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
WO1996011213A1 (en) 1994-10-07 1996-04-18 Amgen Boulder Inc. Dimeric il-4 inhibitors
AUPN477695A0 (en) 1995-08-14 1995-09-07 Commonwealth Scientific And Industrial Research Organisation Gene therapy
GB9626029D0 (en) 1996-12-14 1997-01-29 Univ Leeds EVH-1 vectors
US5998598A (en) 1997-03-10 1999-12-07 The United States Of America, As Represented By The Department Of Health And Human Services Immunoadhesins and methods of production and use thereof
CN1257545A (zh) 1997-04-18 2000-06-21 拜奥根有限公司 Ⅱ型TGF-β受体/免疫球蛋白恒定区融合蛋白
WO1999065948A1 (en) 1998-06-16 1999-12-23 Biogen, Inc. Variant type ii tgf-beta receptor fusion proteins and methods
US6472179B2 (en) 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US7083950B2 (en) 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. High affinity fusion proteins and therapeutic and diagnostic methods for use
ATE407697T1 (de) 1999-07-13 2008-09-15 Bolder Biotechnology Inc Erythropoietin immunglobulin fusionsproteine
WO2001010912A1 (en) 1999-08-09 2001-02-15 Lexigen Pharmaceuticals Corp. Multiple cytokine-antibody complexes
US7638604B2 (en) * 2001-02-23 2009-12-29 Genetics Institute, Llc Monoclonal antibodies against interleukin-22
US20030125251A1 (en) 2001-06-21 2003-07-03 Wakefield Lalage M. Transforming growth factor beta (TGF-beta) antagonist selectively neutralizes "pathological" TGF-beta
WO2003066002A2 (en) * 2002-02-08 2003-08-14 University Of Medicine And Dentistry Of New Jersey IFN-a/b-INDEPENDENT MECHANISM OF ANTIVIRAL PROTECTION
WO2005028517A2 (en) 2003-05-09 2005-03-31 The General Hospital Corporation SOLUBLE TGF-β TYPE III RECEPTOR FUSION PROTEINS
WO2005024027A1 (ja) * 2003-09-02 2005-03-17 National Institute Of Advanced Industrial Science And Technology 抗体医薬
US20090155267A1 (en) * 2005-02-09 2009-06-18 Apollo Life Sciences Limited Molecule and chimeric molecules thereof
CA2597346A1 (en) * 2005-02-14 2006-08-17 Apollo Life Sciences Limited A molecule and chimeric molecules thereof
CN101146825A (zh) * 2005-02-14 2008-03-19 阿波罗生命科学有限公司 分子及其嵌合分子
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20090175819A1 (en) * 2005-11-15 2009-07-09 Apollo Life Sciences Limited Molecule and chimeric molecules thereof
CN101687933B (zh) 2007-05-30 2015-11-25 浦项工科大学校产学协力团 免疫球蛋白融合蛋白
JP2010529859A (ja) 2007-06-15 2010-09-02 ジェンザイム、コーポレーション TGF−βII型受容体の2つのTGF−β結合ドメインを含有する融合タンパク質
WO2010031168A1 (en) 2008-09-17 2010-03-25 National Research Council Of Canada HETERO-MULTIVALENT BINDING AGENTS FOR MEMBERS OF THE TGFβ SUPERFAMILY
JP2011524741A (ja) * 2008-05-27 2011-09-08 協和発酵キリン株式会社 インターロイキン10受容体(il−10r)抗体及び使用方法
JP2011526794A (ja) 2008-07-02 2011-10-20 エマージェント プロダクト デベロップメント シアトル, エルエルシー TGF−βアンタゴニスト多重標的結合性分子
DK2403951T3 (en) 2009-03-02 2016-01-11 Univ California Tumor-selective E1a and E1b adenoviral mutants
US8993524B2 (en) 2010-03-05 2015-03-31 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
PL3489254T3 (pl) 2012-04-30 2023-01-30 Biocon Limited Ukierunkowujące/immunomodulujące białko fuzyjne i sposoby jego otrzymywania
MY186864A (en) 2013-03-12 2021-08-26 Biocon Ltd Fusion immunomodulatory proteins and methods for making same
HK1225742A1 (zh) 2013-08-22 2017-09-15 Acceleron Pharma, Inc. TGF-β受体II型变体及其用途
CN120919282A (zh) 2013-11-21 2025-11-11 布里格姆及妇女医院股份有限公司 用于治疗肺高压的组合物和方法
HRP20210977T1 (hr) 2014-02-10 2021-09-17 Merck Patent Gmbh Ciljano inhibiranje tgf beta
EP3233920B1 (en) 2014-12-19 2020-08-26 Alkermes, Inc. Single chain fc fusion proteins
EP3288965B1 (en) * 2015-04-29 2019-06-26 Mediolanum Farmaceutici S.p.A. A soluble chimeric interleukin-10 receptor and therapeutic use thereof
US20200231652A1 (en) 2015-08-31 2020-07-23 National Research Council Of Canada Tgf-b-receptor ectodomain fusion molecules and uses thereof
US10906957B2 (en) 2016-09-27 2021-02-02 Epicentrx, Inc. Immunomodulatory fusion proteins
US10232053B2 (en) * 2016-12-30 2019-03-19 Trieza Therapeutics, Inc. Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancer

Similar Documents

Publication Publication Date Title
JP2023096044A5 (cg-RX-API-DMAC7.html)
AU2023200608B2 (en) Anti-human papillomavirus 16 E7 T cell receptors
US20250101080A1 (en) Chimeric antigen receptors and uses thereof
CN111699197B (zh) 结合cd137的单结构域抗体
ES2207278T3 (es) Heterominicuerpos.
ES2833162T5 (es) Receptor de antígeno quimérico y su uso
JP2019531728A5 (cg-RX-API-DMAC7.html)
IL273626B1 (en) Fusion proteins and immune modulators
ES2948717T3 (es) Nueva proteína de fusión específica para CD137 y PD-L1
ES2777801T3 (es) Construcción de ácido nucleico para la expresión de más de un receptor de antígeno quimérico
MX2011009810A (es) Composiciones y metodos para usar proteinas de union multiespecificas que comprenden una combinacion anticuerporeceptor.
JP2021519072A5 (cg-RX-API-DMAC7.html)
JP2021521822A5 (cg-RX-API-DMAC7.html)
JP2022542543A (ja) 抗dll3キメラ抗原受容体及びその使用
JP2017184751A (ja) 抗cd276抗体(b7h3)
RU2017130985A (ru) Фармацевтическая композиция и способ снижения ингибирующего эффекта pd-l1 на т-клетки человека
JP2016534717A5 (cg-RX-API-DMAC7.html)
JP2019521643A5 (cg-RX-API-DMAC7.html)
JP2017536091A (ja) 多価メディトープ、メディトープ結合性抗体およびそれらの使用
JP2010509222A5 (cg-RX-API-DMAC7.html)
WO2015164627A1 (en) Chimeric antigen receptors specific to avb6 integrin and methods of use thereof to treat cancer
JP2025161810A (ja) Il-1スーパーファミリーのサイトカインの空間時間的に制限された活性が武装化された免疫応答性細胞
BR112019017713A2 (pt) proteínas quiméricas à base de csf1r
US20240270812A1 (en) Tmigd2 and its derivatives as blockers or binders of cancer-expressed hhla2 for immunotherapies
US20230183351A1 (en) A targeting module comprising pd-l1 and/or pd-l2 for use in a method for stimulating a chimeric antigen receptor mediated immune response in a mammal